PRODUCT TYPES – Page 24

Biologic charge variant shift (CEX) OOS after filling line intervention: data integrity checks for bioassays and analytical similarity packages

“`html Addressing OOS Results from Biologic Charge Variant Shift (CEX) Post-Filling Line Intervention In the highly regulated world of pharmaceutical manufacturing, an out-of-specification (OOS) result stemming from a biologic charge…

Method variability OOS during lifecycle management: CAPA with limited data sets

Identifying the initial signals of method variability is critical in any investigation. Common symptoms include:Click to read the full article.

Biologic stability failure (real-time/accelerated) during CPV trending review: viral safety and contamination response plan with inspection-ready evidence

Symptoms or signals of biologic stability failures typically manifest as deviations in stability data during CPV trending reviews. It is vital to monitor both real-time and accelerated conditions closely. Common…

Method variability OOS during small-batch manufacturing: FDA/EMA communication strategy

Identifying signals related to method variability OOS is essential to prompt response and investigation. Common symptoms may include:Click to read the full article.

Biologic upstream yield drop (OOT) during commercial manufacturing campaign: CAPA package with CQA/CPP risk assessment and effectiveness verification

Identifying early signals of a yield drop in a biologic manufacturing campaign is crucial for timely response and minimization of impacts. Symptoms can manifest in several forms, including:Click to read…

Method variability OOS during regulatory review: CAPA with limited data sets

Detecting symptoms indicative of method variability requires vigilance in monitoring data generated during testing. Common signals may include:Click to read the full article.

Biologic upstream yield drop (OOT) during FDA/EMA inspection readiness: viral safety and contamination response plan with inspection-ready evidence

Identifying symptoms or signals on the manufacturing floor or in the laboratory is pivotal in promptly addressing a drop in biologic upstream yield. Key symptoms may include:Click to read the…

Stability failure with limited batches during regulatory review: CAPA with limited data sets

Identifying abnormal stability results usually starts with observing specific symptoms or signals in the laboratory or manufacturing environment. Common indicators of potential stability failures include:Click to read the full article.

Biologic bioburden excursion pre-sterile filtration after filling line intervention: CAPA package with CQA/CPP risk assessment and effectiveness verification

The initial step in addressing a bioburden excursion is recognizing the symptoms that signal a problem. Common indicators might include:Click to read the full article.

Specification justification gap during inspection readiness: risk-based GMP justification

When a specification justification gap is present, several symptoms may manifest in the lab or on the production floor. Here are some common indicators that alert personnel to potential issues:Click…

Biologic host cell protein (HCP) OOS after upstream media/raw material change: patient safety impact assessment and batch disposition governance

The detection of OOS HCP results can present itself through various signals during routine quality control testing of final outputs. Common symptoms include:Click to read the full article.

Supply interruption risk during small-batch manufacturing: CAPA with limited data sets

Identifying the symptoms or signals of a potential supply interruption is crucial for initiating an effective investigation. Some common symptoms observed on the manufacturing floor or in laboratory settings include:Click…